Sarepta Licenses Up to Three CNS-Targeting Gene Therapies from Lacerta

Sarepta Therapeutics will shell out potentially more than $38 million for rights to up to three preclinical CNS-targeting gene therapy candidates from Lacerta Therapeutics, in a broadening of the buyer’s pipeline of rare neuromuscular disease treatments beyond Duchenne muscular dystrophy (DMD).Through a License, Development and Option Agreement inked by the companies, Sarepta is licensing exclusive rights to a Lacerta treatment for Pompe disease, as well as options to license two additiona